Vés al contingut

Anna Meseguer Navarro

Institucions de les que formen part

Cap de grup
Fisiopatologia renal
Vall Hebron Institut de Recerca

Anna Meseguer Navarro

Institucions de les que formen part

Cap de grup
Fisiopatologia renal
Vall Hebron Institut de Recerca

Línies de recerca

Androgen activity in renal pathophysiology: Identification of androgen-regulated kidney-specific genes and functional characterization of them, in processes of inflammation, oxidative stress and fibrosis underlying chronic kidney disease, hypertension and metabolic syndrome.

Among the genes identified in our laboratory that are kidney-specific and regulated by androgens at the transcriptional level we are particularly focused on the one that codes for the kidney androgen-regulated protein (KAP). Besides characterization of  the functional promoter elements that enable KAP expression in proximal tubule epithelial cells, we have generated a transgenic (Tg) mouse model that overexpresses KAP in proximal tubule cells under the presence of androgens, in order to mimick the endogenous KAP expression pattern. KAP Tg mice show altered lipid metabolism, glycosuria, proteinuria and hypertension, as well as focal segmental glomerulosclerosis mediated by increased oxidative stress. We are currently working in this Tg model and also preparing conditional knock-out mice to further caharacterize the role of KAP in renal pathophysiology. Moreover, we are also studying the role of KAP in the metabolic syndrome. Besides KAP, we are studying the role of KAP-interacting immunophilins  in inflammation and kidney fibrosis.

IP: Anna Meseguer Navarro

Rare inhirited renal diseases

Our group is focused in research in primary or inherited tubular renal diseases, such as Dent’s Disease, Bartter syndrome, Tubular Acidosis, Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis, among others. Currently we are collaborating  with other groups in Spain, within a research project named Renaltube the main purpose of which is to build a database while facilitating access to genotyping in order to improve the clinical and molecular knowledge of primary tubulopathies. Renaltube has a web-based approach with multilateral collaboration scheme that enhances the recruitment of data and promotes the understanding of underlying mechanisms of rare inherited diseases, defines more accurate diagnostic and follow-up criteria, develops new molecular techniques and will improve the overall care of the patients. Currently we are offering the analysis of 22 genes corresponding to 23 primary tubulopathies. After two years of activity Renaltube has collected data from 222 patients, the mayority from Spain and Latin America (85.3%). The most common tubulopathies are distal renal tubular acidosis (22.5%), and classical Bartter syndrome (19.3%) followed by familial hypomagesemia with hipercalciuria and nephrocalcinosis (15.7%), and Gitelman syndrome (15%).

IP: Gema Ariceta Iraola, Anna Meseguer Navarro

Role of HAVRC/KIM-1 in the development and progression of the renal clear cell carcinoma (ccRCC) and in the damage/regeneration renal tubular processes

Overexpression of this protein in 60% of the ccRCCs has already been described. HAVR/KIM-1 overexpression in human ccRCC cell lines blocks cell differentiation and promotes cell scattering. We aim to determine the role of HAVR/KIM-1 in the development and progression of ccRCC, and its possible value as a diagnostic and prognostic biomarker. We also focus on KIM-1’s role in ischemia/reperfusion- or nephrotoxic-induced renal tubular injury. Overexpression of this protein in kidney injury has been described. However, whether its involvement is associated with processes enabling to recover tubular epithelium or potentially increasing damage is not known to this date. With the assistance of cultured renal tubular cell models, we are now investigating whether KIM-1 expression shifts are correlated with renal proximal tubule regeneration ability and, as a consequence, investigating its potential therapeutic application.

IP: Anna Meseguer Navarro

Projectes

La variabilidad fenotípica en pacientes afectados de Hipomagnesemia Familiar con Hipercalciuria y Nefrocalcinosis (HFHNC) como oportunidad para entender las bases fisiopatológicas de la enfermedad y para la búsqueda de soluciones terapéuticas

IP: Anna Meseguer Navarro
Col·laboradors: Gema Ariceta Iraola, Gerard Cantero Recasens
Entitat finançadora: Sociedad Española de Nefrología (S.E.N.)
Finançament: 24000
Referència: SENEFRO/PROJECTES/2023/MESEGUER
Durada: 27/11/2023 - 26/11/2025

Fucosylation in Clear Cell Renal Cell Carcinoma. STATing novel biomarkers and therapeutic strategies

IP: Anna Meseguer Navarro
Col·laboradors: Gerard Cantero Recasens, Miriam Izquierdo Sans
Entitat finançadora: Asociación Española Contra el Cáncer
Finançament: 150000
Referència: INVES234762CANT
Durada: 15/11/2023 - 14/11/2026

KOMPARTE: Sistema digital, multiprofesional, multiplataforma para el registro y explotación de datos del Hospital Universitario Vall d´Hebron.

IP: Alberto Sandiumenge Camps
Col·laboradors: Anna Meseguer Navarro
Entitat finançadora: Diario Médico - Unidad Editorial
Finançament: 0.01
Referència: DM/ENNOVAHEALTH/2022/SANDIUMENGE
Durada: 25/10/2022 - 25/10/2022

Papel del ClC-5 en la fibrosis renal. Identificación de posibles biomarcadores y dianas terapéuticas para la progresión de la enfermedad de Dent 1

IP: Gerard Cantero Recasens
Col·laboradors: Anna Meseguer Navarro, Hector Rios Duro, Mónica Durán Fernández, Gloria Mª Fraga Rodriguez, Julieta Torchia
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 123420
Referència: PI22/00741
Durada: 01/01/2023 - 31/12/2025

Notícies relacionades

El projecte liderat per Hipofam utilitzarà la donació de la Fundació Inocente Inocente per fer una anàlisi funcional de les variants genètiques modificadores del fenotip en pacients afectats d’hipomagnesèmia familiar amb hipercalciúria i nefrocalcinosi.

La recerca liderada pel Dr. Gerard Cantero, del grup de Fisiopatologia Renal, buscarà nous biomarcadors i dianes farmacològiques per al càncer renal de cèl·lula clara.

El projecte, que ha rebut finançament de l’Associació per a la Informació i la Recerca de les Malalties Renals Genètiques, espera ajudar a desenvolupar noves teràpies per a la hipomagnesèmia familiar amb hipercalciúria i nefrocalcinosi.

Professionals relacionats

Ester Palacio Gutierrez

Ester Palacio Gutierrez

Tècnic de recerca
Malalties hepàtiques
Llegir més
Marisol Ruiz Meana

Marisol Ruiz Meana

Investigador/a principal
Malalties cardiovasculars
Llegir més
Olga Luengo Sanchez

Olga Luengo Sanchez

Malalties sistèmiques
Llegir més
Gerard Oristrell Santamaria

Gerard Oristrell Santamaria

Investigador/a predoctoral
Malalties cardiovasculars
Llegir més

Subscriu-te als nostres butlletins i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.